Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The transcription factor C/EBPalpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPalpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We have recently shown mutations in the DNA-binding domain of C/EBP␣ in acute myeloid leukemia, suggesting its importance in granulocyte differentiation and leukemia.19”
From Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions (2002) · cites this paper as [19]
Citations
Cites
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.229 · Cited by 3,486 · cited 1×
“These findings support the concept that CEBPA forms detected with monospecific antibodies are alternative products translated from several in-frame initiation codons by a leaky ribosome-scanning mechanis”
BackgroundThe Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins
Landschulz, W. H., Johnson, P. F., & McKnight, S. L. (1988) · Science · doi:10.1126/science.3289117 · Cited by 3,443
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Isolation of a recombinant copy of the gene encoding C/EBP.
Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., & McKnight, S. L. (1988) · Genes & Development · doi:10.1101/gad.2.7.786 · Cited by 956
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In addition, no mature granulocytes are observed in Cebpa -mutant mice, whereas all the other blood cell types are present in normal proportion”
BackgroundSelf-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“gif" NDATA ITEM> ]> Introduction A number of oncogenes that affect proliferation and cell death have been identified in leukemias and other cancers, but relatively few differentiation genes have been implicated in the malignant phenotyp”
BackgroundSelf-citationCCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712 · cited 1×
“bThe abnormalities were one del(9)(q21), one del(9)(q22q34), one t(6;9), one t(10;21)(p11;q22), one del(7)(q22q34), one +8, one +14, and four complex abnormalities.”
BackgroundRadomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466 · cited 1×
“cThese patients had a 46,XY,del(12)(p11.”
Self-citation
Cited by
Items 201–300 of 930
Clinically useful prognostic factors in acute myeloid leukemia
Ferrara, F., Palmieri, S., & Leoni, F. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.09.008 · Cited by 78
Hock, H. R., & Orkin, S. H. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000190111.85284.8f · Cited by 90
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms
Ernst, T., Chase, A., Zoi, K., Waghorn, K., Hidalgo-Curtis, C., Score, J., Jones, A. V., Grand, F., Reiter, A., Hochhaus, A., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.021808 · Cited by 81
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
Bacher, U., Kern, W., Schnittger, S., Hiddemann, W., Haferlach, T., & Schoch, C. (2005) · PubMed · Cited by 78
Self-citationModern diagnostics in acute leukemias
Haferlach, T., Kern, W., Schnittger, S., & Schoch, C. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.04.008 · Cited by 78
Self-citationMolecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
Haferlach, T. (2008) · Hematology · doi:10.1182/asheducation-2008.1.400 · Cited by 87
Induction of granulocytic differentiation by 2 pathways
Zhang, P., Nelson, E., Radomska, H. S., Iwasaki-Arai, J., Akashi, K., Friedman, A. D., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v99.12.4406 · Cited by 78
“8 Patients with t(8;21) M2 AML do not harbor C/EBP mutations, but the AML1/ETO fusion protein encoded by the translocation results in down-regulation of C/EBP expression.”
Self-citationTranslational control of SCL-isoform expression in hematopoietic lineage choicePreprint
Calkhoven, C. F., Müller, C., Martin, R., Krosl, G., Hoang, T., & Leutz, A. (2003) · Genes & Development · doi:10.1101/gad.251903 · Cited by 77
C/EBPα deregulation as a paradigm for leukemogenesis
Pulikkan, J. A., Tenen, D. G., & Behre, G. (2017) · Leukemia · doi:10.1038/leu.2017.229 · Cited by 79
Self-citationAsou, N. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00003-3 · Cited by 80
Hollink, I. H. I. M., van den Heuvel‐Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Zimmermann, M., Peeters, J. K., Valk, P. J. M., Balgobind, B. V., Sonneveld, E., Kaspers, G. J. L., de Bont, E. S. J. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031336 · Cited by 86
Mannelli, F., Ponziani, V., Bencini, S., Bonetti, M. I., Benelli, M., Cutini, I., Gianfaldoni, G., Scappini, B., Pancani, F., Piccini, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151910 · Cited by 75
Chapiro, É., Russell, L. J., Radford‐Weiss, I., Bastard, C., Lessard, M., Struski, S., Cavé, H., Fert‐Ferrer, S., Barin, C., Maarek, O., et al. (2006) · Blood · doi:10.1182/blood-2006-03-010835 · Cited by 75
Brown, J. M., Jawad, M., Twigg, S. R. F., Saracoglu, K., Sauerbrey, A., Thomas, A. E., Eils, R., Harbott, J., & Kearney, L. (2002) · Blood · doi:10.1182/blood.v99.7.2526 · Cited by 75
Discovery of Epigenetically Masked Tumor Suppressor Genes in Endometrial Cancer
Takai, N., Kawamata, N., Walsh, C., Gery, S., Desmond, J. C., Whittaker, S., Said, J. W., Popoviciu, L. M., Jones, P. A., Miyakawa, I., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0110 · Cited by 81
Role of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia
Koschmieder, S., Rosenbauer, F., Steidl, U., Owens, B. M., & Tenen, D. G. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05051 · Cited by 72
Self-citationHalmos, B., Bassères, D. S. D. S., Monti, S., D‘Aló, F., Dayaram, T., Ferenczi, K., Wouters, B. J., Huettner, C. S., Golub, T. R., & Tenen, D. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4052 · Cited by 78
Self-citationMilde‐Langosch, K., Löning, T., & Bamberger, A. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023929504884 · Cited by 75
Bassères, D. S. D. S., Levantini, E., Ji, H., Monti, S., Elf, S., Dayaram, T., Fenyus, M. L., Kocher, O. N., Golub, T. R., Wong, K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1109-1123.2006 · Cited by 73
Self-citationClara, E. D., Gourvest, M., Ma, H., Vergez, F., Tosolini, M., Dejean, S., Demur, C., Delabesse, É., Récher, C., Touriol, C., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.171645 · Cited by 70
Marcinkowska, E., Garay, E., Gocek, E., Chrobak, A., Wang, X., & Studzinski, G. P. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.03.003 · Cited by 76
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia
Benthaus, T., Schneider, F., Mellert, G., Zellmeier, E., Schneider, S., Kakadia, P. M., Hiddemann, W., Bohlander, S. K., Feuring‐Buske, M., Braess, J., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07328.x · Cited by 70
“Moreover, the functional properties of CEBPA mutations have only been analysed in selected cases (Pabst et al, 2001; Gombart et al, 2002; D’Alo et al, 2003; Schwieger et al, 2004; Hasemann et al, 2008).”
BackgroundInfluentialSelf-citationLoss of CCAAT/enhancer binding protein δ promotes chromosomal instability
Huang, A., Montagna, C., Sharan, S., Ni, Y., Ried, T., & Sterneck, E. (2004) · Oncogene · doi:10.1038/sj.onc.1207285 · Cited by 73
“Point mutations in the CEBPA gene that lead to truncated dominant negative proteins are associated with a subset of acute myeloid leukemia patients (Pabst et al., 2001).”
BackgroundCytogenetics in acute myeloid leukemia
Schoch, C., & Haferlach, T. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0032-0 · Cited by 69
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies
Bacher, U., Haferlach, C., Schnittger, S., Kohlmann, A., Kern, W., & Haferlach, T. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0920-6 · Cited by 75
“[1] or of the CCAAT/ enhancer-binding protein alpha (CEPBA) gene which has a coding function for a critical myeloid transcription factor [2].”
BackgroundSelf-citationKato, N., Kitaura, J., Doki, N., Komeno, Y., Watanabe‐Okochi, N., Togami, K., Nakahara, F., Oki, T., Enomoto, Y., Fukuchi, Y., et al. (2010) · Blood · doi:10.1182/blood-2010-02-270181 · Cited by 74
Wagner, K., Zhang, P., Rosenbauer, F., Drescher, B., Kobayashi, S., Radomska, H. S., Kutok, J. L., Gilliland, D. G., Krauter, J., & Tenen, D. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508143103 · Cited by 66
Self-citationExplaiNN: interpretable and transparent neural networks for genomics
Novakovsky, G., Fornés, O., Saraswat, M., Mostafavi, S., & Wasserman, W. W. (2023) · Genome biology · doi:10.1186/s13059-023-02985-y · Cited by 72
“For example, the Bcl11b unit outputs were confined within the boundaries of the alpha/beta T cell cluster, consistent with its role in the differentiation and survival of these lymphocytes [58], the Cebpa unit outputs within the myeloid cluster, in agreement with its role in myeloid differentiation [59], and the Ebf1…”
ResultFamilial CEBPA-mutated acute myeloid leukemia
Tawana, K., Rio‐Machín, A., Preudhomme, C., & Fitzgibbon, J. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.04.001 · Cited by 67
Böckers, M., Paul, N. W., & Efferth, T. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114977 · Cited by 69
Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3
Argiropoulos, B., Palmqvist, L., Yung, E., Kuchenbauer, F. C., Heuser, M., Sly, L. M., Wan, A., Krystal, G., & Humphries, R. K. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.02.011 · Cited by 70
C/EBPα Is a DNA Damage-Inducible p53-Regulated Mediator of the G 1 Checkpoint in Keratinocytes
Yoon, K., & Smart, R. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10650-10660.2004 · Cited by 74
Transcription factor mutations as a cause of familial myeloid neoplasms
Churpek, J. E., & Bresnick, E. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120854 · Cited by 63
Anastasov, N., Bonzheim, I., Rudelius, M., Klier, M., Dau, T., Angermeier, D., Duyster, J., Pittaluga, S., Fend, F., Raffeld, M. A., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.014050 · Cited by 74
Hypoxia Down-regulates CCAAT/Enhancer Binding Protein-α Expression in Breast Cancer Cells
Seifeddine, R., Dreiem, A., Blanc, E., Fulchignoni-Lataud, M.-C., Belda, M.-A. L. F., Lecuru, F., Mayi, T. H., Mazure, N., Favaudon, V., Massaad, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1190 · Cited by 57
Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA
Konstandin, N. P., Pastore, F., Herold, T., Dufour, A. M., Rothenberg‐Thurley, M., Hinrichsen, T., Ksienzyk, B., Tschuri, S., Schneider, S., Hoster, E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016840 · Cited by 64
Self-citationC/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia
Alberich-Jordà, M., Wouters, B., Balastik, M., Shapiro-Koss, C., Zhang, H., DiRuscio, A., Radomska, H. S., Ebralidze, A. K., Amabile, G., Ye, M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65102 · Cited by 59
Self-citationRangatia, J., Vangala, R. K., Treiber, N., Zhang, P., Radomska, H., Tenen, D. G., Hiddemann, W., & Behre, G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8681-8694.2002 · Cited by 62
Self-citationRangatia, J., Vangala, R. K., Singh, S. M., Peer Zada, A. A., Elsässer, A., Kohlmann, A., Haferlach, T., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206664 · Cited by 62
“…by BCR-ABL (Perrotti et al., 2002; Schuster et al., 2003), AML1-ETO (Pabst et al., 2001a), PML-RARa (Truong et al., 2003), and through mutation (Pabst et al., 2001b), thus being a common target in myeloid leukemias, we hypothesized that elevated c-Jun expression in AML might inactivate C/EBPa…”
BackgroundSelf-citationLu, G., Leung, C. H., Yan, B., Tan, C. M., Low, S. Y., Aung, M. O., Salto–Tellez, M., Lim, S. G., & Hooi, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.051 · Cited by 62
Zebrafish as a model for myelopoiesis during embryogenesis
Berman, J. N., Kanki, J. P., & Look, A. T. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.06.010 · Cited by 69
Akagi, T., Saitoh, T., O'Kelly, J., Akira, S., Gombart, A. F., & Koeffler, H. P. (2008) · Blood · doi:10.1182/blood-2007-04-087213 · Cited by 60
Greif, P. A., Eck, S. H., Konstandin, N. P., Benet‐Pagès, A., Ksienzyk, B., Dufour, A., Vetter, A. T., Popp, H. D., Lorenz‐Depiereux, B., Meitinger, T., et al. (2011) · Leukemia · doi:10.1038/leu.2011.19 · Cited by 70
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML
Maxson, J. E., Ries, R. E., Wang, Y.-C., Gerbing, R. B., Kolb, E. A., Thompson, S. L., Auvil, J. M. G., Marra, M. A., Ma, Y. P., Zong, Z., et al. (2016) · Blood · doi:10.1182/blood-2016-04-709899 · Cited by 62
Ley, T. J., Minx, P. J., Walter, M. J., Ries, R. E., Sun, H., McLellan, M., DiPersio, J. F., Link, D. C., Tomasson, M. H., Graubert, T. A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2335924100 · Cited by 61
C/EBPα Dysregulation in AML and ALL
Paz‐Priel, I., & Friedman, A. (2011) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v16.i1-2.90 · Cited by 72
Pseudokinases: a tribble‐edged sword
Richmond, L., & Keeshan, K. (2019) · FEBS Journal · doi:10.1111/febs.15096 · Cited by 61
Li, Z., Schwieger, M., Lange, C., Kraunus, J., Hanying, S., van den Akker, E., Modlich, U., Serinsöz, E., Will, E., von Laer, D., et al. (2003) · Experimental Hematology · doi:10.1016/j.exphem.2003.08.008 · Cited by 68
“SF91-C/EBPα-iGFP-PRE (R890), and SF91-mut10-iGFP-PRE (R891) were generated by inserting a cDNA for the CCAAT/enhancer binding protein-α or a mutant thereof [42] into R780, respectively.”
MethodShim, M., Powers, K. L., Ewing, S. J., Zhu, S., & Smart, R. C. (2005) · Cancer Research · doi:10.1158/0008-5472.861.65.3 · Cited by 61
Hickey, C. J., Schwind, S., Radomska, H. S., Dorrance, A. M., Santhanam, R., Mishra, A., Wu, Y.-Z., Alachkar, H., Maharry, K. S., Nicolet, D., et al. (2012) · Blood · doi:10.1182/blood-2012-05-428573 · Cited by 62
Self-citationTavor, S., Park, D. J., Gery, S., Vuong, P. T., Gombart, A. F., & Koeffler, H. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307077200 · Cited by 67
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia
Schlenk, R. F., & Döhner, K. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257adb · Cited by 57
Khanna‐Gupta, A., Zibello, T., Sun, H., Gaines, P. C. W., & Berliner, N. (2003) · Blood · doi:10.1182/blood-2002-09-2767 · Cited by 64
Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia
Chim, C. S., Wong, A. S. Y., & Kwong, Y. L. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03952.x · Cited by 57
“The transcription repression might be mediated through inhibition of the positive autoregulation of the CEBPA promoter by C/EBPa (Pabst et al, 2001b).”
BackgroundElagib, K. E., & Goldfarb, A. N. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.010 · Cited by 66
“In a series of 137 patients with AML, 10 samples (∼7%) displayed heterozygous coding mutations which in 5 cases led to the expression of the p30 dominant negative isoform [41].”
BackgroundHiga, K. C., Goodspeed, A., Chavez, J. S., De Dominici, M., Danis, E., Zaberezhnyy, V., Rabe, J. L., Tenen, D. G., Pietras, E. M., & DeGregori, J. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200560 · Cited by 57
Self-citationImplication of the Molecular Characterization of Acute Myeloid Leukemia
Döhner, H. (2007) · Hematology · doi:10.1182/asheducation-2007.1.412 · Cited by 57
Hutt, J. A., & DeWille, J. W. (2002) · PubMed · Cited by 72
Schwieger, M., Löhler, J., Fischer, M., Herwig, U., Tenen, D. G., & Stocking, C. (2003) · Blood · doi:10.1182/blood-2003-07-2280 · Cited by 64
Self-citationMutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7
Langabeer, S. E., Gale, R. E., Rollinson, S. J., Morgan, G. J., & Linch, D. C. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10031 · Cited by 57
“E-mail: stephenl@icr.ac.uk Received 18 June 2001; Accepted 18 September 2001 Published online 1 February 2002 GENES, CHROMOSOMES & CANCER 34:24–32 (2002) DOI 10.1002/gcc.10031 © 2002 Wiley-Liss, Inc. diated through its association with and downregulation of C/EBP (Pabst et al., 2001b).”
BackgroundInfluentialRAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias
Usher, S., Radford, A. D., Villiers, E. J., & Blackwood, L. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.09.005 · Cited by 56
Pulikkan, J. A., Dengler, V., Zada, A. A. P., Kawasaki, A., Geletu, M., Pasalic, Z., Bohlander, S. K., Ryo, A., Tenen, D. G., & Behre, G. (2010) · Leukemia · doi:10.1038/leu.2010.37 · Cited by 62
Self-citationMicroRNA Cancer Regulation: Advanced Concepts, Bioinformatics and Systems Biology Tools
Schmitz, U., Wolkenhauer, O., & Vera, J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1 · Cited by 58
Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells
Nimer, S. D., & Moore, M. A. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207673 · Cited by 64
“Interference with transcription factors that regulate HSC differentiation or self-renewal In addition to blocking AML1-dependent transcriptional activation, AML1-ETO can also block the Oncogene activating effects of C/EBPa (a bZIP protein), ETS proteins such as PU.1 or MEF, and the Smad proteins involved in the TGFb r…”
BackgroundInfluentialIkezoe, T., Gery, S., Yin, D. X., O’Kelly, J., Binderup, L., Lemp, N. A., Taguchi, H., & Koeffler, H. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-3619 · Cited by 62
Haefliger, S., Klebig, C., Schaubitzer, K., Schardt, J., Timchenko, N. A., Mueller, B. U., & Pabst, T. (2011) · Blood · doi:10.1182/blood-2010-08-304485 · Cited by 60
Self-citationC/EBPα and DEK coordinately regulate myeloid differentiation
Koleva, R., Ficarro, S. B., Radomska, H. S., Carrasco-Alfonso, M. J., Alberta, J. A., Webber, J. T., Luckey, C. J., Marcucci, G., Tenen, D. G., & Marto, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-383083 · Cited by 61
Self-citationCEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
Lin, T.-C., Hou, H.-A., Chou, W.-C., Ou, D., Yu, S., Tien, H., & Lin, L. (2010) · Leukemia · doi:10.1038/leu.2010.222 · Cited by 55
Potential role of sorafenib in the treatment of acute myeloid leukemia
Mori, S., Cortes, J. E., Kantarjian, H. M., Zhang, W., Andreef, M., & Ravandi, F. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802510349 · Cited by 56
Vegesna, V., Takeuchi, S., Hofmann, W.-K., Ikezoe, T., Tavor, S., Krug, U., Fermin, A. C., Heaney, A., Miller, C. W., & Koeffler, H. P. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00150-3 · Cited by 54
Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation
Rishi, L., Hannon, M., Salomè, M., Hasemann, M. S., Frank, A.-K., Campos, J., Timoney, J., O’Connor, C., Cahill, M. R., Porse, B. T., et al. (2014) · Blood · doi:10.1182/blood-2013-07-511683 · Cited by 61
Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions
Su, L., Shi, Y., Liu, Z., & Gao, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806137 · Cited by 54
“The first study was published in 2001, reporting that CEBPA mutations were identified in 10 of 137 patients with AML, which was also the first report showing CEBPA mutations in human neoplasia (14).”
BackgroundQuintanilla‐Martínez, L., Pittaluga, S., Miething, C., Klier, M., Rudelius, M., DAVIES-HILL, T. M., Anastasov, N., Martínez, A., Vivero, A., Duyster, J., et al. (2006) · Blood · doi:10.1182/blood-2005-10-014258 · Cited by 57
The origin of hematopoietic cell type diversity
Hoang, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207937 · Cited by 54
Targeting transcription factors in acute myeloid leukemia
Takei, H., & Kobayashi, S. S. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2488-1 · Cited by 53
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael, E. C., Georgiou, G. K., Benetatos, L., & Briasoulis, E. C. (2013) · Europe PMC (PubMed Central) · Cited by 65
Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation
Renneville, A., Mialou, V., Philippe, N., Kagialis‐Girard, S., Biggio, V., Zabot, M.-T., Thomas, X., Bertrand, Y., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.294 · Cited by 55
The rationale for deltanoids in therapy for myeloid leukemia: Role of KSR–MAPK–C/EBP pathway
Studzinski, G. P., Wang, X., Ji, Y., Wang, Q., Zhang, Y., Kutner, A., & Harrison, J. S. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.06.010 · Cited by 53
Koschmieder, S., D'Alò, F., Radomska, H., Schöneich, C., Chang, J. S., Konopleva, M., Kobayashi, S., Levantini, E., Suh, N., Di Ruscio, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-058941 · Cited by 50
Self-citationKummalue, T., & Friedman, A. D. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.1202622 · Cited by 52
Trivedi, A. K., Bararia, D., Christopeit, M., Zada, A. A. P., Singh, S. M., Kieser, A., Hiddemann, W., Behre, H. M., & Behre, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209964 · Cited by 58
“Potential antagonistic protein interactions leading to a block in C/EBPa function in AML have been well implicated in recent findings (Pabst et al., 2001a; Vangala et al., 2003; Zheng et al., 2004).”
InfluentialSelf-citationRegulation of granulocyte and monocyte differentiation by CCAAT/enhancer binding protein α
Friedman, A. D., Keefer, J. R., Kummalue, T., Liu, H., Wang, Q., & Cleaves, R. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00135-9 · Cited by 58
Paz‐Priel, I., Cai, D. H., Wang, D., Kowalski, J., Blackford, A. L., Liu, H., Heckman, C. A., Gombart, A. F., Koeffler, H. P., Boxer, L. M., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0111 · Cited by 55
“t(8;21) generally express lower levels of bcl-2 compared with other AMLs (31) and thus supports the biological relevance of the correlation between CEBPA and Bcl-2 .”
InfluentialYoshino, S., Yokoyama, T., Sunami, Y., Takahara, T., Nakamura, A., Yamazaki, Y., Tsutsumi, S., Aburatani, H., & Nakamura, T. (2020) · Blood · doi:10.1182/blood.2019004586 · Cited by 58
Wierenga, A. T. J., Schepers, H., Moore, M. A. S., Vellenga, E., & Schuringa, J. J. (2006) · Blood · doi:10.1182/blood-2005-11-4608 · Cited by 55
The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia
Owen, C., Fitzgibbon, J., & Paschka, P. (2009) · Hematological Oncology · doi:10.1002/hon.931 · Cited by 67
Tan, E. H., Hooi, S. C., Laban, M., Wong, E., Ponniah, S., Wee, A., & Wang, N.-D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4486 · Cited by 52
Puig-Kröger, A., Sánchez-Elsner, T., Ruiz, N., Andreu, E. J., Prosper, F., Jensen, U. B., Gil, J., Erickson, P., Drabkin, H., Groner, Y., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0618 · Cited by 51
Signal Transduction in the Liver: C/Ebpβ Modulates Cell Proliferation and Survival
Buck, M., & Chojkier, M. (2003) · Hepatology · doi:10.1053/jhep.2003.50155 · Cited by 57
Molecular Mechanisms of Myelodysplastic Syndrome
Hirai, H. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg037 · Cited by 62
Prognostic impact of CEBPA mutational subgroups in adult AML
Georgi, J.-A., Stasik, S., Krämer, M., Meggendorfer, M., Röllig, C., Haferlach, T., Valk, P. J. M., Linch, D. C., Herold, T., Duployez, N., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02140-x · Cited by 50
Self-citationThe Prognostic Value of CXCR4 in Acute Myeloid Leukemia
Ahn, J. Y., Seo, K., Weinberg, O. K., & Arber, D. A. (2012) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3182606f4d · Cited by 50
Acetylation of C/EBPα inhibits its granulopoietic function
Bararia, D., Kwok, H. S., Welner, R. S., Numata, A., Sárosi, M. B., Yang, H., Wee, S., Tschuri, S., Ray, D., Weigert, O., et al. (2016) · Nature Communications · doi:10.1038/ncomms10968 · Cited by 49
Self-citationTargeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression
Yong, K. J., Bassères, D. S. D. S., Welner, R. S., Zhang, W. C., Yang, H. H., Yan, B., Alberich-Jordà, M., Zhang, J., de Figueiredo‐Pontes, L. L., Battelli, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6066 · Cited by 56
Self-citationProlyl Isomerase Pin1 in Human Cancer: Function, Mechanism, and Significance
Pu, W., Zheng, Y., & Peng, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00168 · Cited by 52
“Because transcriptional factors of Pin1 are generally overactivated by upstream oncogenic signaling (Pabst et al., 2001; Giuli et al., 2019; Kent and Leone, 2019), the above-mentioned evidence gives an explanation, at least in part, for the upregulation of Pin1 in cancer cells.”
BackgroundDifferential Regulation of Primitive Myelopoiesis in the Zebrafish by Spi-1/Pu.1 and C/ebp1
Su, F., Juarez, M. A., Cooke, C. L., LaPointe, L., Shavit, J. A., Yamaoka, J. S., & Lyons, S. E. (2007) · Zebrafish · doi:10.1089/zeb.2007.0505 · Cited by 46
Carroll, K. D., Khadim, F., Spadavecchia, S., Palmeri, D., & Lukac, D. M. (2007) · Journal of Virology · doi:10.1128/jvi.00265-07 · Cited by 54
Shim, M., & Smart, R. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301356200 · Cited by 56
Akagi, T., Thoennissen, N. H., George, A., Crooks, G. M., Song, J. H., Okamoto, R., Nowak, D., Gombart, A. F., & Koeffler, H. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015419 · Cited by 59
Development of macrophages of cyprinid fish
Hanington, P. C., Tam, J., Katzenback, B. A., Hitchen, S. J., Barreda, D. R., & Belosevic, M. (2008) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2008.11.004 · Cited by 53
Metadata
- Authors
- Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Genetics
- Published
- 2001-03
- Volume
- 27
- Issue
- 3
- Pages
- 263-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2100088478
- Cited by
- 901
- References
- 33
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 30 · 2021: 22 · 2020: 27 · 2019: 17 · 2018: 22 · 2017: 27 · 2016: 29 · 2015: 47 · 2014: 37 · 2013: 34 · 2012: 50
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- CEBPA, C/EBPα, acute myeloid leukemia, dominant negative mutation, heterozygous mutation, transcription factors, granulocytic differentiation, DNA binding, transcriptional activation, N-terminal truncation
- MeSH terms
- Base Sequence, Cell Differentiation, Cell Nucleus, DNA, Neoplasm, Genes, Dominant, Granulocytes, Heterozygote, Humans, Mutation, Neutrophils, Leukemia, Myeloid, Acute, Transcriptional Activation, Sequence Deletion, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.